Fragile X Associated Tremor Ataxia Syndrome and Fragile X Associated Primary Ovarian Failure

Slide 1 · Fragile X–Associated Tremor/Ataxia Syndromeand Fragile X–Associated Primary Ovarian Failure

Molecular pathology · neurological and reproductive phenotypes

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Explain why an FMR1 premutation causes disease without classic FMR1 silencing.

Relate toxic FMR1 RNA to late-onset neurological dysfunction and ovarian insufficiency.

Recognize FXTAS and FXPOI presentations, diagnostic clues, and family implications.

Slide 3 · Three phenotypes, one gene

Disorder

Molecular context

Defining phenotype

Fragile X syndrome (FXS)

Full mutation, FMR1 silencing, deficient FMRP

Usually childhood-onset neurodevelopmental phenotype

FXTAS

Premutation, toxic RNA-associated mechanism

Late-onset progressive tremor–ataxia phenotype

FXPOI

Premutation, ovarian dysfunction

Hypergonadotropic ovarian insufficiency before 40

Slide 4 · Premutations are not phenotypically silent

A CGG premutation can be transmitted without classic fragile X syndrome.

Some carriers later develop neurologic disease; Some females develop ovarian insufficiency.

Clinical risk is incompletely penetrant: Carrier status does not guarantee either outcome.

Premutation carrier

Risk of FXTAS or FXPOI

Some remain without these syndromes

Slide 5 · FMR1 is located on the X chromosome

The FMR1 gene lies at Xq27.3.

CGG repeats are in the 5′ untranslated region—not the protein-coding sequence.

The expansion can alter transcriptional regulation or RNA behavior depending on repeat range.

FMR1 locus · Xq27.3

5′ UTR

Coding

CGG repeat expansion in 5′ UTR

Slide 6 · What is a CGG repeat expansion?

CGG is a three-nucleotide sequence repeated in tandem within FMR1.

Repeat lengths are unstable across some generations.

Increased repeat size can cause distinct molecular outcomes—not simply a graded form of one disease.

FMR1 DNA repeat tract

CGG

CGG

CGG

CGG

Repeat number varies by allele and across generations

Slide 7 · Interpret repeat ranges carefully

Allele class

CGG repeats

Clinical interpretation

Typical/normal

<45

Generally stable, not the premutation phenotype

Intermediate

45–54

Borderline stability; not FXTAS or FXPOI by itself

Premutation

~55–200

Associated with FXTAS and FXPOI risk

Full mutation

>200

Usually hypermethylated; associated with FXS

Slide 8 · Repeat-size boundaries are operational

Repeat classification is based on allele size plus methylation and family context.

GeneReviews emphasizes that boundaries at the margins are not absolute.

For smaller premutations, AGG interruptions affect maternal expansion risk.

Repeat count

Methylation / AGG pattern

Family and phenotype

Slide 9 · Full mutation: Gene silencing dominates

A large CGG expansion usually triggers methylation involving the FMR1 promoter.

Methylation suppresses FMR1 transcription and reduces FMRP production.

The primary phenotype is fragile X syndrome—not the canonical premutation phenotype.

Full mutation

Promoter methylation

Low FMR1 expression

FMRP deficiency

Slide 10 · Premutation: Transcription persists

The premutation is generally not associated with the full-mutation hypermethylation pattern.

Expanded-repeat FMR1 transcripts continue to be produced; Levels can be increased.

RNA-mediated toxicity is a proposed principal mechanism of premutation disorders.

Premutation

FMR1 remains active

Expanded-repeat mRNA

RNA-associated toxicity

Slide 11 · Loss of protein versus toxic RNA

Phenotype

Repeat category

Gene behavior

Main pathogenic model

FXS

Full mutation

Transcriptional silencing

Loss of functional FMRP

FXTAS / FXPOI

Premutation

FMR1 RNA remains expressed

Toxic gain of function (proposed)

Slide 12 · The expanded repeat is noncoding

A CGG expansion in the 5′ UTR is not a polyglutamine expansion.

Its pathogenic effect is linked to gene regulation and the behavior of abnormal RNA.

This differs mechanistically from coding-region CAG expansion disorders such as Huntington disease.

Noncoding CGG: RNA / regulation

Coding CAG: Abnormal protein

Slide 13 · A molecular model of RNA sequestration

Expanded FMR1 RNA can bind and sequester RNA-binding proteins.

Sequestration reduces the availability of these proteins at their normal functional sites.

The resulting disruption is a proposed link between RNA expansion and tissue injury.

Expanded FMR1 RNA

RNA-binding proteins recruited

Normal protein function impaired

Slide 14 · Intranuclear inclusions are a tissue clue

Abnormal FMR1 RNA and recruited proteins can aggregate in nuclei.

Nuclear inclusions in central and peripheral nervous systems.

The presence of inclusions supports a tissue-level manifestation of RNA-associated toxicity.

Nuclear inclusions: Conceptual schematic

Slide 15 · What intranuclear inclusions do—and do not—prove

Inclusions are a characteristic neuropathologic finding in FXTAS.

They support the molecular diagnosis in appropriate tissue and clinical context.

A visible aggregate does not, by itself, establish every downstream injury mechanism.

Observed inclusion

Molecular association

Causal interpretation remains qualified

Slide 16 · The ovarian mechanism is less settled

FMR1 RNA-containing aggregates have been reported in granulosa and ovarian stromal cells.

Premature follicular loss has been proposed as a consequence.

Robbins explicitly presents this ovarian injury mechanism as a hypothesis, not a confirmed complete pathway.

Premutation RNA in ovarian cells

Reported aggregates

Possible follicular injury

Slide 17 · Same premutation: Organ-selective phenotypes

Affected system

Primary dysfunction

Typical clinical window

Nervous system

Progressive motor, cognitive and other neurological changes

Late-adult expression of disease

Ovary

Impaired ovarian function / depleted reserve

Reproductive-age expression of disease

Slide 18 · Why premutation testing has broad meaning

It may explain a neurological syndrome, an ovarian syndrome, or both patterns across a family.

It also informs the potential for repeat expansion in the next generation.

The laboratory result should be interpreted together with phenotype and reproductive history.

Individual diagnosis

Family segregation

Reproductive counseling

Slide 19 · FXTAS: A late-onset neurodegenerative syndrome

FXTAS stands for fragile X-associated tremor/ataxia syndrome.

It is associated with a premutation-sized FMR1 allele.

The hallmark clinical presentation combines progressive intention tremor and cerebellar ataxia.

FMR1 premutation

Later-life neurological onset

Progressive tremor / ataxia

Slide 20 · Age at presentation matters

Typical onset beginning in the sixth decade of life.

GeneReviews gives a usual onset around 60–65 years, with wide individual variation.

A late-onset neurological disorder in a premutation carrier differs from childhood FXS.

Childhood: FXS

Adult: Carrier often well

Older adult: Possible FXTAS

Slide 21 · FXTAS often begins with action tremor

Intention tremor is a major clinical criterion for FXTAS.

Tremor may precede clinically obvious gait ataxia.

The combination and progression are more informative than the presence of tremor alone.

Intention tremor

Gait incoordination

Possible cognitive decline

Slide 22 · Intention tremor: The clinical concept

The tremor appears or increases during goal-directed movement.

It is consistent with dysfunction in cerebellar motor control pathways.

Do not equate any tremor, particularly an isolated rest tremor, with FXTAS.

Goal-directed movement

Tremor near target

Evaluate accompanying ataxia

Slide 23 · Cerebellar gait ataxia is a major sign

Cerebellar gait ataxia is a second major clinical criterion.

Impaired gait and postural stability are important causes of functional decline.

Progressive imbalance in an older premutation carrier warrants neurological evaluation.

Cerebellar dysfunction

Impaired coordination

Gait / fall risk

Slide 24 · Motor manifestations extend beyond ataxia

Parkinsonism may develop as FXTAS progresses.

Lower-extremity neuropathy can coexist with central movement dysfunction.

Phenotypic overlap with other neurodegenerative syndromes can complicate diagnosis.

Tremor and ataxia

Parkinsonian features

Peripheral nerve findings

Slide 25 · Parkinsonism is not the defining sign

Parkinsonism is classified as a minor clinical criterion in established FXTAS criteria.

Tremor and cerebellar gait ataxia are the major clinical findings.

An apparent Parkinson disease phenotype alone is not sufficient to diagnose FXTAS.

Major: Intention tremor / gait ataxia

Minor: Parkinsonism

Slide 26 · Peripheral neuropathy adds disability

Neuropathy in the lower extremities is a minor clinical feature.

Sensory or motor impairment may aggravate balance difficulty.

Both central cerebellar and peripheral nerve contributions deserve examination.

Neuropathy

Reduced distal function

Additional instability

Slide 27 · Executive dysfunction is an early cognitive pattern

Cognitive decline can begin with executive function difficulties.

Working memory and processing speed may subsequently be involved.

Cognitive manifestations should be assessed rather than assumed to be age-related.

Executive function deficit

Working memory affected

Broader cognitive impairment

Slide 28 · Short-term memory loss in FXTAS

Moderate-to-severe short-term memory deficiency is a minor clinical criterion.

Cognitive findings often accompany a motor syndrome rather than defining it alone.

Dementia in an older person with ataxia or tremor is a reason to consider FMR1 testing.

Motor syndrome

Memory / executive findings

Consider genetic explanation

Slide 29 · Psychiatric symptoms may coexist

Anxiety, depression, irritability and apathy have been reported in FXTAS.

These symptoms can add clinically meaningful impairment.

Their presence is supportive context, not a specific diagnostic substitute for motor findings.

Mood and behavior

Neurological phenotype

Whole-person assessment

Slide 30 · Autonomic and other neurological findings

Autonomic dysfunction and lower-limb proximal weakness are among reported associated features.

Neuropathic pain may occur with peripheral neuropathy.

These findings widen the clinical assessment but are not uniquely diagnostic of FXTAS.

Autonomic dysfunction

Weakness / neuropathic pain

Motor / cognitive syndrome

Slide 31 · MRI: Middle cerebellar peduncle sign

White-matter lesions in the middle cerebellar peduncles constitute the major radiologic criterion.

This pattern is commonly called the MCP sign.

The sign must be interpreted in clinical and genetic context; It is not an isolated proof of FXTAS.

MCP sign = peduncle white-matter signal

Schematic; Not a patient MRI

Slide 32 · Other MRI abnormalities are minor criteria

White-matter lesions in cerebral white matter may be observed.

Splenial white-matter lesions are included among minor radiologic findings.

Moderate-to-severe generalized brain atrophy is also a minor criterion.

Cerebral white-matter lesions

Splenium lesions

Generalized atrophy

Slide 33 · Clinical–radiologic convergence is essential

The premutation establishes susceptibility, not by itself clinical FXTAS.

Progressive clinical signs must be weighed alongside imaging patterns.

Alternative causes of tremor, ataxia and white-matter abnormalities require assessment.

Premutation established

Clinical motor syndrome

Supportive MRI findings

Slide 34 · Diagnostic criteria: Major and minor signs

Class

Findings

Clinical major

Intention tremor; cerebellar gait ataxia

Clinical minor

Parkinsonism; memory deficiency; executive dysfunction; leg neuropathy

Radiologic major

MCP white-matter lesions

Radiologic minor

Cerebral white-matter lesions; splenial lesions; generalized atrophy

Slide 35 · Definite FXTAS: Accepted pathways

A premutation carrier can meet definite criteria with one major radiologic plus one major clinical sign.

A characteristic neuropathologic inclusion finding also qualifies in the defined criteria.

The criteria describe diagnostic confidence, not a stand-alone imaging screening result.

FMR1 premutation

MCP sign + major clinical sign

Definite FXTAS

Slide 36 · Probable FXTAS: Two combinations

One major radiologic sign plus one minor clinical sign meets probable criteria.

Alternatively, two major clinical signs meet probable criteria.

The latter pattern allows a probable diagnosis without the major radiologic sign.

Major MRI + minor clinical

Two major clinical signs

Slide 37 · Possible FXTAS: One specified combination

One minor radiologic sign plus one major clinical sign meets possible criteria.

This category expresses lower certainty than definite or probable.

It should be interpreted with molecular testing and exclusion of competing causes.

Minor radiologic sign

Major clinical sign

Possible FXTAS

Slide 38 · The neuropathologic hallmark is nuclear

FXTAS inclusions are found within cell nuclei, including neuronal and astrocytic nuclei.

GeneReviews describes characteristic eosinophilic, ubiquitin-positive intranuclear inclusions.

These are genuine morphologic criteria; The slide schematic is not a photomicrograph.

Nuclear inclusions: Conceptual schematic

Slide 39 · A diagnostic work-up is phenotype driven

Consider FXTAS in adults with otherwise unexplained intention tremor and gait ataxia.

Review family history for fragile X syndrome and premature ovarian insufficiency.

Confirm premutation status with specialized FMR1 CGG repeat testing.

Clinical suspicion

Three-generation family history

Targeted FMR1 testing

Slide 40 · Differential diagnosis: Motor syndromes

Common alternative diagnostic categories include parkinsonism, essential/other tremor syndromes and hereditary ataxias.

Multiple system atrophy, cerebellar subtype, can resemble FXTAS.

Evaluate the chronology, phenotype, imaging and genetic result together.

Tremor disorders

Ataxia syndromes

Parkinsonian syndromes

Slide 41 · Differential diagnosis: Cognition and white matter

Dementia, cerebrovascular disease and other leukoencephalopathies may overlap clinically or radiologically.

The MCP sign is helpful but not independently pathognomonic.

A premutation plus compatible clinical evidence strengthens attribution.

Motor / cognitive phenotype

MRI white-matter findings

Rule out alternatives

Slide 42 · FXTAS penetrance increases with age

Risk (%) of FXTAS in male premutation carriers by age

0

20

40

60

80

17%

50–59

38%

60–69

47%

70–79

75%

≥80

Estimated FXTAS risk by age among males with an FMR1 premutation (GeneReviews, Table 2; Adapted from Grigsby et al).

Slide 43 · Sex modifies FXTAS penetrance

Premutation-carrying males are more frequently affected than females.

GeneReviews reports about 40% among males older than 50 and 16%–20% among female carriers.

Age and ascertainment affect prevalence estimates; Sex is not an absolute determinant.

Males: Higher penetrance

Females: Lower, nonzero risk

Slide 44 · Repeat length also modifies neurological risk

Higher CGG repeat size within the premutation range correlates with increased FXTAS risk and severity.

Reported associations include earlier onset and greater motor impairment.

Genotype–phenotype correlation is probabilistic, not a deterministic forecast for one person.

Longer premutation repeat

Higher population-level risk

Not certain individual outcome

Slide 45 · Functional consequences of progressive FXTAS

Gait and postural instability can lead to need for walking aids.

Cognitive impairment can compromise complex daily activities.

Therapeutic priorities emphasize symptom control, falls prevention and multidisciplinary support.

Motor / cognitive decline

Safety and independence affected

Supportive care needs

Slide 46 · FXTAS management is supportive

No established therapy reverses the underlying FMR1 RNA-associated process.

Management addresses tremor, ataxia, neuropathic symptoms and cognitive/psychiatric complications.

Rehabilitation and individualized fall-risk assessment are clinically important.

Symptom management

Rehabilitation and safety

Cognitive / mental health support

Slide 47 · FXPOI: The reproductive phenotype of a premutation

FXPOI is ovarian insufficiency attributable to an FMR1 premutation.

It occurs before age 40 and is associated with elevated gonadotropin concentrations.

Not every premutation-carrying woman develops the ovarian phenotype.

Premutation carrier

Reduced ovarian function

Possible FXPOI before 40

Slide 48 · Why “ovarian insufficiency” is preferred

The Robbins section uses “primary ovarian failure”; Current terminology favors “primary ovarian insufficiency.”

Ovarian activity can be intermittent rather than completely or permanently absent.

The newer terminology avoids implying inevitable and absolute sterility.

Older: Ovarian failure

Preferred: Ovarian insufficiency

Slide 49 · FXPOI affects only a subset of carriers

Premature ovarian failure in approximately one-fifth of female premutation carriers.

A carrier result alone does not diagnose ovarian insufficiency.

Clinical menstrual history and biochemical assessment are necessary.

FMR1 premutation

Increased risk of POI

Only some carriers affected

Slide 50 · Age threshold distinguishes primary ovarian insufficiency

FXPOI is defined by ovarian insufficiency before 40 years of age.

The relevant phenotype is hypergonadotropic hypogonadism.

Earlier menopause by itself is not interchangeable with confirmed FXPOI.

Age <40

Ovarian functional decline

Gonadotropin elevation

Slide 51 · Menstrual changes are a clinical entry point

Cycle irregularity, oligomenorrhea or amenorrhea may prompt evaluation.

Irregular menses in a carrier should not automatically be attributed to FXPOI.

Pregnancy and other endocrine or gynecologic causes must still be considered.

Menstrual change

Evaluate common causes

Assess for POI and FMR1

Slide 52 · Elevated FSH reflects reduced ovarian feedback

Follicle-stimulating hormone can rise when ovarian endocrine feedback declines.

Elevated FSH as a marker of declining ovarian function in affected carriers.

Interpreting FSH requires clinical and reproductive context rather than an isolated value.

Ovarian endocrine insufficiency

Reduced feedback

Increased FSH

Slide 53 · AMH gives information about ovarian reserve

Anti-Müllerian hormone is often decreased as ovarian reserve declines.

Reduced AMH in affected premutation carriers.

Low AMH supports diminished reserve, but NFXF cautions that it is not independently diagnostic of POI.

FSH: Gonadotropic response

AMH: Ovarian reserve marker

Slide 54 · Ovarian dysfunction has a continuum

An individual may first develop menstrual irregularity and evidence of diminished reserve.

Persistently elevated FSH may accompany hypergonadotropic ovarian insufficiency.

Some spontaneous ovarian activity may remain even after POI diagnosis.

Diminishing ovarian reserve

Irregular cycles / endocrine change

Clinical POI; Activity can vary

Slide 55 · FXPOI affects fertility—but is not absolute infertility

Premutation carriers with FXPOI have reduced fertility.

Spontaneous ovulation and pregnancy may still occur after POI diagnosis.

Counseling should address both fertility planning and contraception as appropriate.

Reduced fertility

Intermittent ovarian function possible

Individualized family planning

Slide 56 · Menopause may occur earlier in carriers

Menopause approximately five years earlier than in controls on average.

The finding describes a population comparison, not the expected age for every carrier.

Premutation carriers without diagnosed FXPOI may nevertheless experience altered reproductive timing.

Typical menopause in controls

Earlier average in premutation carriers

Wide individual variation

Slide 57 · Ovarian cellular inclusions: Cautious interpretation

Expanded FMR1 RNA-containing aggregates have been detected in granulosa cells.

Ovarian stromal cells can also contain aggregates.

These reports suggest a tissue correlate but do not prove the complete sequence of follicular injury.

Granulosa / stromal RNA aggregates reported

Ovarian schematic — not histology

Slide 58 · Premature follicle loss remains a hypothesis

That abnormal RNA aggregates might trigger premature follicular death.

The available textbook discussion does not establish all intermediate molecular pathways.

Separate demonstrable histopathologic observation from a proposed causal mechanism.

RNA-containing aggregates observed

Mechanism incompletely known

Possible follicular attrition

Slide 59 · Clinical consequences of hypoestrogenism

Estrogen deficiency may produce vasomotor symptoms, vaginal dryness and sexual discomfort.

Long-term health concerns include reduced bone mineral density.

Attention to cardiovascular and overall health belongs in POI management.

Symptoms

Bone health

Cardiovascular risk

Slide 60 · Current FXPOI diagnostic approach

2025 NFXF guidance describes absent menstrual periods for at least four months before age 40.

A serum FSH value in the menopausal range (>25 IU/L) is part of that guidance.

Guidelines have evolved; Confirm locally applicable criteria before using a threshold clinically.

Age <40 + amenorrhea ≥4 months

FSH >25 IU/L

Evaluate cause, including FMR1

Slide 61 · The literature uses differing FSH criteria

GeneReviews (2024) describes earlier criteria requiring two elevated FSH levels at least one month apart.

The NFXF 2025 consensus description uses a single menopausal-range FSH level.

These criteria should be identified by publication and date rather than merged.

GeneReviews 2024: 2 FSH samples

NFXF 2025: 1 menopausal-range FSH

Slide 62 · Screen for FMR1 premutation in POI

NFXF 2025 recommends premutation testing in women diagnosed with POI.

A negative family history does not exclude an inherited FMR1 premutation.

A positive result also creates implications for other relatives and future pregnancies.

Confirmed primary ovarian insufficiency

Targeted FMR1 repeat analysis

Genetic counseling / family assessment

Slide 63 · Other causes of amenorrhea remain relevant

Evaluate pregnancy, thyroid disease, hyperprolactinemia and hypothalamic causes when clinically indicated.

Polycystic ovary syndrome can also produce irregular menses.

Not all irregular menses in a premutation carrier is caused by FXPOI.

Pregnancy / hypothalamic causes

Thyroid / prolactin disorders

PCOS / other gynecologic disorders

Slide 64 · Alternative causes of established POI

Other POI etiologies include chromosome disorders such as Turner syndrome.

Autoimmune causes and prior gonadotoxic treatment require consideration.

The molecular diagnosis of FXPOI should be made in the context of the full clinical work-up.

Chromosomal causes

Autoimmune causes

Iatrogenic injury

Slide 65 · FXPOI care addresses long-term health

Gynecologic or reproductive endocrine specialist input is appropriate.

Hormone replacement is generally recommended for POI when no contraindication exists.

Bone-density assessment, cardiovascular considerations and psychosocial support may be relevant.

Hormonal health

Bone / vascular health

Fertility and psychosocial care

Slide 66 · Counseling must preserve reproductive nuance

An FXPOI diagnosis does not rule out spontaneous conception.

Genetic transmission risk persists if conception occurs.

Preconception discussion can include molecular counseling and reproductive options.

Intermittent ovarian activity

Potential conception

FMR1 transmission counseling

Slide 67 · X-linked inheritance creates multi-generation risk

FMR1 is an X-linked locus: Sex of the transmitting parent affects inheritance.

Premutation transmission by a mother may involve CGG expansion to a full mutation.

A transmitting male passes his FMR1 premutation to all daughters, not sons.

Paternal X to daughters; Paternal Y to sons

Simplified transmission diagram

Slide 68 · Transmission is not equivalent to disease

Inheriting a premutation conveys risk of FXTAS/FXPOI and repeat expansion; It does not guarantee disease.

An expanded maternal premutation may cause FXS in a child if it becomes a full mutation.

Phenotype and molecular repeat size must be kept separate in pedigrees.

Allele transmission

Repeat stability / expansion

Clinical expression

Slide 69 · Maternal expansion: Why anticipation matters

Premutation-to-full-mutation amplification during oogenesis.

This helps explain why classic FXS may emerge in later generations.

Risk is influenced by repeat size and sequence interruptions; A counseling assessment is individualized.

Maternal premutation

Possible expansion in oogenesis

Full-mutation FXS in offspring

Slide 70 · Paternal premutations follow a different pattern

A hemizygous premutation-carrying father transmits the allele to daughters.

He transmits his Y chromosome—not the FMR1-bearing X chromosome—to sons.

Paternal transmission typically does not generate a full-mutation expansion.

Paternal X to daughters; Paternal Y to sons

Simplified transmission diagram

Slide 71 · FMR1 testing is not routine sequencing

Diagnostic evaluation requires repeat-sizing methods targeted to FMR1 CGG expansions.

Repeat-primed PCR can identify the expanded-repeat locus and AGG interruptions.

Methylation testing is particularly relevant to classifying a full mutation.

Clinical indication

Targeted CGG repeat assay

Classify allele / methylation

Slide 72 · Why a standard exome may miss an expansion

Routine exome or gene panels may not adequately characterize FMR1 CGG repeat length.

GeneReviews recommends specialized molecular analysis for suspected FMR1-associated disorders.

Do not interpret an unrevealing generic panel as exclusion of FXTAS or FXPOI.

Targeted repeat assay: Indicated

Ordinary exome alone: Insufficient

Slide 73 · Molecular result versus clinical diagnosis

Evidence

What it contributes

Interpretation

Premutation detected

Establishes genotype and susceptibility

Does not alone confirm FXTAS or FXPOI

Clinical syndrome documented

Establishes phenotype

Requires appropriate differential diagnosis

Both together

Connects genotype and phenotype

Supports FMR1-associated diagnosis

Slide 74 · Case: Older adult with progressive imbalance

A 68-year-old man develops intention tremor and progressive cerebellar gait ataxia.

MRI shows middle cerebellar peduncle white-matter lesions.

A targeted test detects an FMR1 premutation.

Which diagnostic category is supported by these findings?

Interpretation: Definite FXTAS: One major radiologic sign (MCP sign) plus at least one major clinical sign, in a premutation carrier.

Slide 75 · Case: No major MRI abnormality

A premutation-carrying older adult has intention tremor and cerebellar gait ataxia.

MRI does not demonstrate an MCP lesion.

No neuropathologic examination has been performed.

Is definite FXTAS established by the given criteria?

Interpretation: No. Two major clinical signs meet probable FXTAS criteria; An MCP lesion or inclusions are not shown.

Slide 76 · Case: Reproductive-endocrine presentation

A 32-year-old woman presents with persistent amenorrhea and elevated FSH.

Molecular testing identifies a premutation-sized FMR1 allele.

She reports a family member affected by fragile X syndrome.

What two dimensions of care are required?

Interpretation: Evaluate/manage primary ovarian insufficiency and provide reproductive genetic counseling for FMR1 transmission risk.

Slide 77 · Case: Do not equate a low AMH with POI

A premutation-carrying woman has decreased AMH but continues regular menstrual cycles.

She has no reported amenorrhea meeting POI criteria.

A low ovarian-reserve marker is not sufficient as a stand-alone diagnosis.

Can FXPOI be diagnosed solely from low AMH?

Interpretation: No. AMH may indicate diminished reserve, but a clinical/biochemical POI evaluation is still required.

Slide 78 · Comparative clinicopathologic diagnosis

Condition

Clinical domain

Characteristic presentation

Supporting evaluation

FXTAS

Neurological

Intention tremor + cerebellar ataxia

MRI / selected neuropathology + repeat test

FXPOI

Reproductive-endocrine

POI before age 40

Menstrual/FSH evaluation + repeat test

FXS

Neurodevelopmental

Childhood developmental impairment

Full-mutation/methylation testing

Slide 79 · Five errors to avoid in interpretation

Premutation ≠ full mutation; Gain-of-function model ≠ transcriptional silencing.

Carrier status ≠ inevitable penetrance of FXTAS or FXPOI.

MRI signal ≠ standalone FXTAS diagnosis; Low AMH ≠ standalone POI diagnosis.

Reported ovarian aggregates ≠ fully established causal mechanism.

An FMR1 phenotype can have genetic implications beyond the index patient.

Genotype ≠ phenotype

Supportive test ≠ stand-alone proof

Observation ≠ complete causal model

Slide 80 · Integrated mechanism and phenotype

Genotype

Transcription

Pathogenesis

Phenotype

FMR1 full mutation

Promoter hypermethylation

Reduced FMRP

Fragile X syndrome

FMR1 premutation

Expanded RNA remains expressed

RNA-associated toxicity

FXTAS / FXPOI

Slide 81 · Core teaching synthesis

FXTAS and FXPOI result from FMR1 premutation-associated disease risk, not from the classical FXS silencing mechanism.

FXTAS is a late-onset motor–cognitive syndrome with characteristic clinical and MRI clues.

FXPOI is ovarian insufficiency before 40 with reproductive, endocrine and familial consequences.

Specialized molecular testing and pedigree interpretation link both disorders.

Slide 82 · Selected references

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. 2026; Chapter 5, pp. 153–156.

Hunter JE, Berry-Kravis E, Hipp H, et al. FMR1 Disorders. GeneReviews; revision May 16, 2024.

Fragile X Clinical & Research Consortium. FXPOI treatment recommendation. National Fragile X Foundation; March 2025.